- Home
- GNTY vs ATAI Comparison
GNTY vs ATAI Comparison
Compare GNTY & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNTY
- ATAI
- Stock Information
- Founded
- GNTY 1913
- ATAI 2018
- Country
- GNTY United States
- ATAI Germany
- Employees
- GNTY N/A
- ATAI N/A
- Industry
- GNTY Major Banks
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- GNTY Finance
- ATAI Health Care
- Exchange
- GNTY Nasdaq
- ATAI Nasdaq
- Market Cap
- GNTY 520.5M
- ATAI 444.7M
- IPO Year
- GNTY 2017
- ATAI 2021
- Fundamental
- Price
- GNTY $47.80
- ATAI $4.65
- Analyst Decision
- GNTY Buy
- ATAI Strong Buy
- Analyst Count
- GNTY 2
- ATAI 3
- Target Price
- GNTY $44.50
- ATAI $13.33
- AVG Volume (30 Days)
- GNTY 38.9K
- ATAI 4.7M
- Earning Date
- GNTY 10-20-2025
- ATAI 11-12-2025
- Dividend Yield
- GNTY 2.10%
- ATAI N/A
- EPS Growth
- GNTY 38.57
- ATAI N/A
- EPS
- GNTY 3.15
- ATAI N/A
- Revenue
- GNTY $127,325,000.00
- ATAI $2,309,000.00
- Revenue This Year
- GNTY $10.99
- ATAI $661.36
- Revenue Next Year
- GNTY $4.83
- ATAI N/A
- P/E Ratio
- GNTY $15.14
- ATAI N/A
- Revenue Growth
- GNTY 10.12
- ATAI 510.85
- 52 Week Low
- GNTY $32.04
- ATAI $1.03
- 52 Week High
- GNTY $50.50
- ATAI $5.34
- Technical
- Relative Strength Index (RSI)
- GNTY 50.57
- ATAI 52.96
- Support Level
- GNTY $48.30
- ATAI N/A
- Resistance Level
- GNTY $49.41
- ATAI $4.75
- Average True Range (ATR)
- GNTY 0.78
- ATAI 0.27
- MACD
- GNTY -0.20
- ATAI -0.21
- Stochastic Oscillator
- GNTY 4.76
- ATAI 93.19
About GNTY Guaranty Bancshares Inc.
Guaranty Bancshares Inc is a bank holding company conducting banking activities through its wholly-owned subsidiary. The company provides its customers with a full array of relationship-driven commercial and consumer banking products and services, as well as mortgage, trust, and wealth management products and services that are tailored to meet the needs of small and medium-sized businesses, professionals, and individuals. It also provides other services such as Credit cards, Personal Loans, Business Checking, Treasury Management, and other related services. The company generates its revenue from interest on loans and investments, customer service and loan fees, fees related to the sale of mortgage loans, and trust and wealth management services.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.